The major themes of this project are (a) linkage of laboratory observations with clinically relevant data in a systematic Fashion and (b) exploration of mechanism-based new approaches to therapy in CLL. Available databases and cell banks will be expanded in a carefully coupled fashion to optimize the translational element of the research. New approaches to therapy with unique exploitable mechanisms of action will be explored. The clinical endpoints will be related specifically to pharmacodynamic, cell death and genetic measurements in these protocols.
Aim 1 a) To prospectively collect relevant clinical data at the time when cell and serum samples are sent to laboratory investigators or banks. b) To study the emergence of new prognostic factors as CLL progresses. c) To correlate molecular, genetic, cell death, and immunologic data with clinical events. We will use this data to develop a model of CLL as a genetically-driven, evolving, dedifferentiating disease. d) To study the prognostic impact of clinical and laboratory data using multivariate modeling techniques.
Aim 2 a) To develop treatment of paradigms with the goal of achieving true complete remissions in CLL (PCR negative for Ig gene rearrangement). b) To develop efficient phase II clinical trials of new agents coupled with pharmacodynamic and mechanistic studies. c) To introduce new agents with unique mechanisms of action into phase I clinical trials in CLL.
Aim 3 To develop a comprehensive profile of molecular events and protein expression exposure profiles on patients with CLL at different phases of the disease. Prognostic significance for response to therapy and survival will be sought.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory Grants (P20)
Project #
1P20CA081534-01
Application #
6259053
Study Section
Subcommittee G - Education (NCI)
Project Start
1999-05-01
Project End
2000-04-30
Budget Start
Budget End
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Veronese, A; Pepe, F; Chiacchia, J et al. (2015) Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. Leukemia 29:86-95
Maji, Santanu; Samal, Sabindra K; Pattanaik, Laxmipriya et al. (2015) Mcl-1 is an important therapeutic target for oral squamous cell carcinomas. Oncotarget 6:16623-37
Wu, Bainan; Barile, Elisa; De, Surya K et al. (2015) High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists. Curr Top Med Chem 15:2032-42
Wu, Bainan; Wang, Si; De, Surya K et al. (2015) Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells. Chem Biol 22:876-887
Lamothe, Betty; Cervantes-Gomez, Fabiola; Sivina, Mariela et al. (2015) Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia. Blood 125:407-10
Laganà, Alessandro; Acunzo, Mario; Romano, Giulia et al. (2014) miR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAs. Nucleic Acids Res 42:5416-25
McClanahan, Fabienne; Gribben, John (2014) Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies? Hematol Oncol Clin North Am 28:1055-71
Vamos, Mitchell; Welsh, Kate; Finlay, Darren et al. (2013) Expedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAP. ACS Chem Biol 8:725-32
Hudson, Robert S; Yi, Ming; Volfovsky, Natalia et al. (2013) Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer. Mol Cancer 12:13
Balakrishnan, Kumudha; Gandhi, Varsha (2013) Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs 31:1384-94

Showing the most recent 10 out of 46 publications